Premium
Cadila shares up 3 pct on USFDA nod
Cadila Healthcare rose more than 3 per cent after the company said it got US FDA approval to conduct phase-I trials for a diabetes drug.
Shares of Cadila Healthcare rose more than 3 per cent after the company said it got US FDA approval to conduct phase-I trials for a diabetes drug.
At 11.12 a.m.,shares of the company were up 2.63 per cent at Rs 824.
You have exhausted your
monthly limit of free stories.
Read more stories for free
with an Express account.
Read this and every other premium story with a digital subscription.
This premium article is free for now.
Register to continue reading this story
Read this and every other premium story with a digital subscription.
This content is exclusive for our subscribers.
Subscribe now to get unlimited access to The Indian Express exclusive and premium stories.
